세계의 폐렴구균 백신 시장 규모는 2024년 98억 달러에 달했습니다. 향후 IMARC 그룹은 2033년까지 시장 규모가 149억 달러에 달하고, 2025-2033년 연평균 성장률(CAGR)은 4.48%를 보일 것으로 예측했습니다. 이 시장은 패혈증과 폐렴 증가, 고령화, 의료비 지출 증가, 정부 기관의 노력과 자금 조달, 규제 당국의 지원과 승인, 공중 보건 캠페인, 백신 기술의 발전 등에 의해 주도되고 있습니다.
의료비 지출 증가
높은 의료비 지출은 정부 및 민간 의료 부문이 백신 접종 프로그램에 더 많은 투자를 할 수 있게 하여 폐렴구균 백신에 대한 접근성과 비용 효율성을 향상시켜 전체 인구의 백신 접종률을 향상시킬 수 있습니다. 이에 따라 의료비 지출 증가는 백신 접종 클리닉, 유통망, 훈련된 의료 전문가 등 의료 인프라의 개선으로 이어지는 경우가 많습니다. 이러한 인프라는 폐렴구균 백신의 관리와 옹호를 돕고 시장 성장에 기여합니다. 또한, 높은 의료비 지출은 제약회사의 연구 개발(R&D) 활동에 대한 투자 증가로 이어져 더 효과적이고, 더 많은 혈청형을 커버하며, 더 적은 용량을 필요로 하는 폐렴구균 백신을 강화하는 데 도움이 될 수 있습니다. 메디케어-메디케이드 서비스 센터 웹사이트에 2024년 업데이트된 내용에 따르면, GDP 대비 의료비 비중은 2022년 17.3%에서 2032년 19.7%로 확대될 것으로 예측됩니다.
고령화 진행
노인은 면역력 저하와 기저질환으로 인해 폐렴, 침습성 폐렴구균 감염 등 폐렴구균 감염에 걸리기 쉽습니다. 이러한 취약성 증가는 심각한 질병을 피하기 위해 폐렴구균 백신의 높은 이용률로 이어지고 있습니다. 또한, 많은 정부 기관 및 의료 기관에서 정기 예방접종 일정의 일환으로 노인층에 대한 폐렴구균 백신 접종을 권장하고 있어 의료 종사자 및 노인들이 백신 접종을 우선순위로 삼고 있어 폐렴구균 백신에 대한 수요를 촉진하고 있습니다. 또한, 의료 부문은 노인의 건강을 개선하고 병원 재입원을 최소화하기 위해 노인의 예방 치료 전략을 우선순위에 두고 있습니다. 세계보건기구(WHO) 웹사이트에 게재된 기사에 따르면, 60세 이상 고령자는 2050년까지 두 배로 증가하여 전 세계적으로 약 21억 명에 달할 것으로 예측됩니다.
패혈증 유병률 증가
세계보건기구(WHO) 웹사이트에 2024년 업데이트된 내용에 따르면, 전 세계적으로 추정되는 패혈증 환자 중 2,000만 명에 가까운 숫자가 5세 미만 소아에서 발생한다고 합니다. 폐렴구균 감염의 원인인 폐렴구균은 패혈증의 주요 원인 중 하나이며, 특히 면역력이 저하된 소아에서 증가하고 있습니다. 폐렴구균 감염으로 인한 패혈증 발생이 증가함에 따라 백신 접종 등 예방적 접근의 중요성이 강조되고 있습니다. 또한, 폐렴구균에 대한 백신 접종은 패혈증을 유발할 수 있는 폐렴구균 감염을 포함하여 폐렴구균 감염의 위험을 크게 감소시킵니다. 폐렴구균 감염을 예방함으로써 백신은 의료 환경에서 패혈증에 대한 전반적인 부담을 줄이는 데 도움이 됩니다. 이와는 별도로 폐렴구균 감염을 예방함으로써 의료 현장의 패혈증에 대한 전반적인 부담을 줄일 수 있습니다. 또한, 패혈증에 대한 방어 전략으로 폐렴구균 백신을 투여함으로써 그 매출이 증가하고 있습니다. 전 세계 공중 보건 개입에서 백신 접종을 통한 패혈증 이환율 및 사망률 예방이 시장 성장을 뒷받침하고 있습니다.
The global pneumococcal vaccine market size reached USD 9.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.9 Billion by 2033, exhibiting a growth rate (CAGR) of 4.48% during 2025-2033. The market is driven by the growing occurrence of sepsis and pneumonia diseases, rising aging population, increasing healthcare spending, governing agencies initiatives and funding, regulatory support and approvals, public health campaigns, and advancements in vaccine technology.
Rising healthcare spending
High healthcare spending allows governments and private healthcare sectors to invest more in vaccination programs, leading to enhanced access and cost-effectiveness of pneumococcal vaccines, thereby increasing vaccination coverage rates across populations. In line with this, increasing healthcare spending often translates into better healthcare infrastructure, including vaccination clinics, distribution networks, and trained healthcare professionals. This infrastructure aids in the management and advocacy for pneumococcal vaccines, thus contributing to the growth of the market. Furthermore, high healthcare spending can lead to an increasing investment in research and development (R&D) activities by pharmaceutical companies, which encourages the enhancement of pneumococcal vaccines that work better, cover more serotypes or need fewer doses. According to the content updated in 2024 on the website of the Centers for Medicare & Medicaid Services, the health spending share of GDP is forecasted to grow from 17.3 percent in 2022 to 19.7 percent in 2032.
Growing aging population
Older people are more prone to pneumococcal infections, including pneumonia or invasive pneumococcal disease, due to weakened immune systems and underlying health conditions. This increasing vulnerability is leading to high utilization of pneumococcal vaccines to avoid such severe illnesses. Besides this, many governing agencies and healthcare organizations recommend pneumococcal vaccination for elderly populations as part of routine immunization schedules, which encourages healthcare providers and older adults to prioritize vaccination, thereby driving the pneumococcal vaccine demand. In addition, healthcare sectors prioritize preventive care strategies for aging populations to improve their health and minimize hospital readmissions. An article published on the website of the World Health Organization (WHO) shows that individuals aged over 60 are expected to double by 2050, reaching nearly 2.1 billion worldwide.
Increasing prevalence of sepsis
As per the content updated in 2024 on the website of the World Health Organization (WHO), almost 20 million of all estimated sepsis cases worldwide occurred in children under 5 years of age. Streptococcus pneumoniae, which causes pneumococcal infections, is one of the leading causes of sepsis, especially among children those with weakened immune systems. The rising occurrence of sepsis caused by pneumococcal infections underlines the importance of preventive approaches such as vaccination. In addition, vaccination against Streptococcus pneumoniae significantly reduces the risk of pneumococcal infections, including those that can lead to sepsis. By preventing pneumococcal diseases, vaccines help mitigate the overall burden of sepsis in healthcare settings. Apart from this, they reduce the overall burden of sepsis in care settings by preventing pneumococcal diseases. Furthermore, the administration of pneumococcal vaccines as a protective strategy against sepsis is increasing their sales. Prevention of sepsis morbidity and mortality through vaccination in public health intervention across the globe is supporting the market growth.
Pneumococcal conjugate vaccine accounts for the majority of the market share
The pneumococcal conjugate vaccine (PCV) is one of the most important products in the market because of its effectiveness in improving public health particularly among children below five years and elderly people. PCVs are aimed at offering protection against various serotypes of the streptococcus pneumoniae bacterium, which is known to cause severe and sometimes fatal conditions such as pneumonia, meningitis, and sepsis. PCVs have been proven to be effective in reducing the incidence of these diseases, which makes it possible to be incorporated in national immunization programs.
Prevnar 13 holds the largest share of the industry
Prevnar 13 is highly preferable due to its effectiveness in preventing infections caused by Streptococcus pneumoniae bacteria. This vaccine is particularly notable for its broad coverage against thirteen different strains of the bacteria. Its incorporation in national immunization programs worldwide is greatly impacting the cases of pneumococcal diseases especially in young children and older individuals. Moreover, its well-established clinical effectiveness and safety profile are ensuring its escalated utilization throughout the world, making it an essential pillar of modern healthcare systems in combating pneumococcal diseases.
Non-governmental organizations (NGO) represent the leading market segment
Non-governmental organizations (NGO) contribute to market dynamics through various initiatives, including funding support for vaccination programs, raising awareness about the importance of pneumococcal immunization, and collaborating with governments and pharmaceutical companies to ensure affordability and availability of vaccines. NGOs also engage in R&D activities to improve vaccine efficacy and promote vaccination campaigns aimed at vulnerable populations such as children and the elderly. Their advocacy efforts also address socio-economic disparities in healthcare access, making pneumococcal vaccines more accessible and impactful worldwide.
Children, especially infants and toddlers, are highly vulnerable to pneumococcal infections, which can lead to serious illnesses, such as pneumonia, meningitis, and sepsis. Vaccination against pneumococcus bacteria is therefore recommended as part of routine childhood immunization schedules worldwide. The effectiveness of pneumococcal vaccines in preventing these infections is significantly reducing morbidity and mortality rates among children globally. Moreover, public health initiatives and immunization programs focused on pediatric populations are contributing to the pneumococcal vaccines market statistics.
As adults are aging, especially those over 65 or with underlying health conditions, they are becoming more vulnerable to pneumococcal infections, which can lead to serious illnesses, such as pneumonia, meningitis, and septicemia. Vaccination in adults helps reduce the risk of these infections and their associated complications, improving overall health outcomes and reducing healthcare costs. Additionally, adults often serve as carriers of pneumococcal bacteria, potentially spreading it to more vulnerable populations like children and the elderly people.
North America leads the market, accounting for the largest pneumococcal vaccine market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for pneumococcal vaccine.
As per the content updated in 2023 on the website of Centers for Medicare & Medicaid Services, U.S. health care spending grew 4.1 percent in 2022, reaching $4.5 trillion or $13,493 per person. The increasing healthcare expenditure reflects a greater emphasis on improving patient outcomes and reducing overall healthcare costs through innovative technologies. Moreover, North America has stringent regulatory frameworks and strong government support for immunization programs that contribute significantly to the growth of the market. The prevalence of pneumococcal diseases in North America, coupled with increasing awareness among healthcare professionals and the general population about the benefits of vaccination, is also driving the demand for pneumococcal vaccines.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)